Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Exclusion Criteria

• •History of clinical manifestation of any flavivirus infection
• •History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)
• •Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine
• •Immunodeficiency including post-organ-transplantation or immunosuppressive therapy
• •A family history of congenital or hereditary immunodeficiency
• •History of autoimmune disease
• •Any acute infections within 4 weeks prior to enrollment
• •Infection with HIV, Hepatitis B or Hepatitis C
• •Pregnancy, lactation or unreliable contraception in female subjects